|Assessment Status||Rapid Review complete|
|Indication||Treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy.|
|Rapid review commissioned||09/11/2021|
|Rapid review completed||16/12/2021|
|Rapid review outcome||A full HTA is not recommended. The NCPE recommends that baricitinib not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.